The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

  • V Novotny-Diermayr, S Hart, K C Goh, A Cheong, L-C Ong, H Hentze, M K Pasha, R Jayaraman, K Ethirajulu, J M Wood
  • Blood Cancer Journal, May 2012, Springer Science + Business Media
  • DOI: 10.1038/bcj.2012.14

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr veronica diermayr